DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
LABRADIMIL
2
Protein
Investigational
Unknown
Unknown
Glioma; Medulloblastoma; Meningitis, Cryptococcal; Central Nervous System Neoplasms
Bradykinin B2 receptor agonist
LABRADIMIL
×
Maximum Phase:
2
First Approval:
None
UNII:
2MK663C346
Molecule Type:
Protein
Molecular Formula:
C49H75N15O12S
Molecular Weight:
1098.3
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GHRP-1
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GHRP-1
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY2623091
2
Small molecule
Investigational
Unknown
Unknown
Essential Hypertension; Renal Insufficiency, Chronic
Mineralocorticoid receptor antagonist
LY2623091
×
Maximum Phase:
2
First Approval:
None
UNII:
6FHZ595FNM
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLEMBATUMUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Squamous Cell; Breast Neoplasms; Melanoma; Osteosarcoma
Transmembrane glycoprotein NMB binding agent
GLEMBATUMUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
1568H6A58U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMONAFIDE DIHYDROCHLORIDE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
AMONAFIDE DIHYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAL
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; HIV Infections
Parathyroid hormone-related protein inhibitor
CAL
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-1512
2
Antibody
Investigational
Unknown
Unknown
Unknown
P-selectin inhibitor
RG-1512
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TAS-108
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TAS-108
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PHENCYNONATE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Motion Sickness
Unknown
PHENCYNONATE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
54F576E38V
Molecule Type:
Small molecule
Molecular Formula:
C22H32ClNO3
Molecular Weight:
393.96
AlogP:
3.34
PSA:
49.77
HBD:
1.0
HBA:
#RotB:
4.0
Source:
COTADUTIDE
2
Protein
Investigational
Unknown
Unknown
Obesity; Renal Insufficiency; Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease
Glucagon-like peptide 1 receptor agonist
COTADUTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
QL6A9B13HW
Molecule Type:
Protein
Molecular Formula:
C167H252N42O55
Molecular Weight:
3728.09
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
NRX-101
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
NRX-101
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BAY1067197
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure
Adenosine A1 receptor agonist
BAY1067197
×
Maximum Phase:
2
First Approval:
None
UNII:
IV690462VZ
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUVADAXISTAT
2
Small molecule
Investigational
Unknown
Unknown
Friedreich Ataxia; Schizophrenia
Unknown
LUVADAXISTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
76IC00YRVR
Molecule Type:
Small molecule
Molecular Formula:
C13H11F3N2O2
Molecular Weight:
284.24
AlogP:
2.28
PSA:
65.98
HBD:
2.0
HBA:
#RotB:
3.0
Source:
ERITORAN
2
Small molecule
Investigational
Unknown
Unknown
Insulin Resistance
Unknown
ERITORAN
×
Maximum Phase:
2
First Approval:
None
UNII:
551541VI0Y
Molecule Type:
Small molecule
Molecular Formula:
C66H126N2O19P2
Molecular Weight:
1313.68
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CL-184
2
Antibody
Investigational
Unknown
Unknown
Unknown
Glycoprotein inhibitor
CL-184
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZD-1480
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Primary Myelofibrosis; Stomach Neoplasms; Thrombocythemia, Essential
Tyrosine-protein kinase JAK2 inhibitor
AZD-1480
×
Maximum Phase:
2
First Approval:
None
UNII:
KL2Z2TLF01
Molecule Type:
Small molecule
Molecular Formula:
C14H14ClFN8
Molecular Weight:
348.77
AlogP:
3.01
PSA:
104.3
HBD:
3.0
HBA:
#RotB:
5.0
Source:
LITGENPROSTUCEL-L
2
Cell
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Unknown
LITGENPROSTUCEL-L
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MGTA-456
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MGTA-456
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UDONITRECTAG
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UDONITRECTAG
×
Maximum Phase:
2
First Approval:
None
UNII:
2GOW9TT6AD
Molecule Type:
Small molecule
Molecular Formula:
C20H19NO5
Molecular Weight:
353.37
AlogP:
1.83
PSA:
76.07
HBD:
1.0
HBA:
#RotB:
5.0
Source:
MILVEXIAN
2
Small molecule
Investigational
Unknown
Unknown
Thrombosis
Unknown
MILVEXIAN
×
Maximum Phase:
2
First Approval:
None
UNII:
0W79NDQ608
Molecule Type:
Small molecule
Molecular Formula:
C28H23Cl2F2N9O2
Molecular Weight:
626.46
AlogP:
5.8
PSA:
125.41
HBD:
1.0
HBA:
#RotB:
4.0
Source:
FORODESINE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Biphenotypic, Acute; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, T-Cell, Cutaneous
Unknown
FORODESINE
×
Maximum Phase:
2
First Approval:
None
UNII:
426X066ELK
Molecule Type:
Small molecule
Molecular Formula:
C11H14N4O4
Molecular Weight:
266.26
AlogP:
-2.02
PSA:
134.26
HBD:
6.0
HBA:
#RotB:
2.0
Source:
AT-9283
2
Small molecule
Investigational
Unknown
Unknown
Leukemia; Lymphoma, Non-Hodgkin; Neoplasms; Multiple Myeloma
Serine/threonine-protein kinase Aurora-A inhibitor
AT-9283
×
Maximum Phase:
2
First Approval:
None
UNII:
XAV9KYN9WL
Molecule Type:
Small molecule
Molecular Formula:
C19H23N7O2
Molecular Weight:
381.44
AlogP:
2.07
PSA:
110.96
HBD:
4.0
HBA:
#RotB:
5.0
Source:
ETHYL ISOTHIOCYANATE
2
Small molecule
Investigational
Unknown
Unknown
Lung Neoplasms
Unknown
ETHYL ISOTHIOCYANATE
×
Maximum Phase:
2
First Approval:
None
UNII:
3284MJ2T8P
Molecule Type:
Small molecule
Molecular Formula:
C3H5NS
Molecular Weight:
87.15
AlogP:
1.11
PSA:
12.36
HBD:
0.0
HBA:
#RotB:
1.0
Source:
ENECADIN
2
Small molecule
Investigational
Unknown
Unknown
Stroke
Unknown
ENECADIN
×
Maximum Phase:
2
First Approval:
None
UNII:
VR034VW8OG
Molecule Type:
Small molecule
Molecular Formula:
C21H28FN3O
Molecular Weight:
357.47
AlogP:
4.63
PSA:
38.25
HBD:
0.0
HBA:
#RotB:
8.0
Source:
DALPICICLIB
2
Small molecule
Investigational
Unknown
Unknown
Esophageal Neoplasms
Unknown
DALPICICLIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H30N6O2
Molecular Weight:
446.56
AlogP:
4.02
PSA:
101.8
HBD:
2.0
HBA:
#RotB:
5.0
Source:
DAIDZEIN
2
Small molecule
Investigational
Unknown
Unknown
Osteoporosis
Unknown
DAIDZEIN
×
Maximum Phase:
2
First Approval:
None
UNII:
6287WC5J2L
Molecule Type:
Small molecule
Molecular Formula:
C15H10O4
Molecular Weight:
254.24
AlogP:
2.87
PSA:
70.67
HBD:
2.0
HBA:
#RotB:
1.0
Source:
IMISOPASEM MANGANESE
2
Small molecule
Investigational
Unknown
Unknown
Hypotension
SOD mimic (antioxidant)
IMISOPASEM MANGANESE
×
Maximum Phase:
2
First Approval:
None
UNII:
2Q6R3259KS
Molecule Type:
Small molecule
Molecular Formula:
C21H35Cl2MnN5
Molecular Weight:
483.39
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CETILISTAT
2
Small molecule
Investigational
Unknown
Unknown
Obesity
Gastric lipase inhibitor
CETILISTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
LC5G1JUA39
Molecule Type:
Small molecule
Molecular Formula:
C25H39NO3
Molecular Weight:
401.59
AlogP:
7.36
PSA:
52.33
HBD:
0.0
HBA:
#RotB:
16.0
Source:
DIHYDREXIDINE
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
DIHYDREXIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
Q3PJ4B4D0X
Molecule Type:
Small molecule
Molecular Formula:
C17H17NO2
Molecular Weight:
267.33
AlogP:
2.65
PSA:
52.49
HBD:
3.0
HBA:
#RotB:
0.0
Source:
FORALUMAB
2
Antibody
Investigational
Unknown
Unknown
Crohn Disease; Graft vs Host Disease
T cell surface glycoprotein CD3 inhibitor
FORALUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
J43DL56H6M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TMC-647055
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
TMC-647055
×
Maximum Phase:
2
First Approval:
None
UNII:
11BD024G7J
Molecule Type:
Small molecule
Molecular Formula:
C32H38N4O6S
Molecular Weight:
606.75
AlogP:
4.16
PSA:
110.18
HBD:
1.0
HBA:
#RotB:
2.0
Source:
OZANEZUMAB
2
Antibody
Investigational
Unknown
Unknown
Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Amyotrophic Lateral Sclerosis
Reticulon-4 inhibitor
OZANEZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
123I05210W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DRF-10945
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Peroxisome proliferator-activated receptor alpha agonist
DRF-10945
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XEN-D0501
2
Small molecule
Investigational
Unknown
Unknown
Cough; Diabetes Mellitus, Type 2; Pulmonary Disease, Chronic Obstructive
Vanilloid receptor antagonist
XEN-D0501
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TASIDOTIN
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
TASIDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
05G07285DK
Molecule Type:
Protein
Molecular Formula:
C32H58N6O5
Molecular Weight:
606.85
AlogP:
2.09
PSA:
122.37
HBD:
2.0
HBA:
#RotB:
11.0
Source:
1
2
…
181
182
183
184
185
186
187
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA